Home > Rheumatology > EULAR 2019 > Psoriatic Arthritis > Efficacy and safety of bimekizumab in patients with active PsA

Efficacy and safety of bimekizumab in patients with active PsA

Presented By
Dr Christopher Ritchlin, University of Rochester Medical Centre, USA
EULAR 2019
Phase 2, BE ACTIVE
Dual neutralisation of IL-17A and IL-17F with bimekizumab was linked to substantial improvements in both musculoskeletal and skin outcomes in patients with active psoriatic arthritis (PsA). Response rates increased after week 12 and were sustained from week 24 to 48. “Patients achieved similar ACR and PASI responses as compared with the overall study population. The safety profile of bimekizumab was consistent with previous reports, and bimekizumab is currently being evaluated in phase 3 trials” concluded Dr Christopher Ritchlin (University of Rochester Medical Centre, USA) [1]. Therapeutic options for psoriasis include biologic drugs such as tumour necrosis factor inhibitors (TNFi) and IL-12/23 inhibitors. Bimekizumab is a monoclonal antibody that selectively neutralises both, IL-17 homo-, and heterodimers,” said Dr Ritchlin. “The rationale for blocking both IL-17A and IL-17F is the recent discovery that both contribute to the development of PsA. IL-17A a...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on